

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **JOINT COMPANY SECRETARIES**

Reference is made to the announcement of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) dated 9 January 2014 (the “**Announcement**”) in relation to the appointment of Ms. Wong Sau Kuen (“**Ms. Wong**”) as the joint company secretary of the Company with effect from 8 January 2014.

As disclosed in the Announcement, the Company had applied for, and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) had granted, a waiver (the “**Waiver**”) from strict compliance with the requirements under Rule 3.28 and Rule 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) for a period of three years from the date of appointment of Ms. Wong as the joint company secretary of the Company (the “**Waiver Period**”) on the conditions that (i) Ms. Wong would be assisted by Mr. Liu Kwok Wah (“**Mr. Liu**”), an executive director and the other joint company secretary of the Company, during the Waiver Period to acquire the “relevant experience” under Note 2 to Rule 3.28 of the Listing Rules and to discharge her duties as a company secretary of the Company, and this Waiver would be revoked immediately if Mr. Liu ceased to provide assistance to Ms. Wong; and (ii) the Company should notify the Stock Exchange at the end of the Waiver Period for the Stock Exchange to re-visit the situation. The Waiver expired on 7 January 2017 (the “**Waiver Expiry Date**”).

During the Waiver Period, Ms. Wong had worked closely and jointly with Mr. Liu in the performance and discharge of the duties of a company secretary under the Listing Rules, including but not limited to handling the Company’s secretarial and compliance matters and participating in corporate actions of the Company, and had attended not less than 15 hours of relevant professional training each year during the Waiver Period. Through the aforementioned, the Company considers that Ms. Wong has the relevant experience capable of discharging the functions of company secretary under Note 2 to Rule 3.28 of the Listing Rules.

Towards the end of the Waiver Period, the Company notified the Stock Exchange of the relevant experience acquired by Ms. Wong as a joint company secretary of the Company during the Waiver Period. On 11 January 2017, the Stock Exchange confirmed that Ms. Wong is qualified to act as a company secretary of the Company under Rule 3.28 of the Listing Rules.

The board of directors of the Company is pleased to announce that Ms. Wong and Mr. Liu would continue to act as the joint company secretaries of the Company after the Waiver Expiry Date.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 13 January 2017

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*